This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Aditya K. Gupta, MD, FRCP(C); Leslie L. Rocher, MD; Stephen P. Schmaltz, MPH, MS; Michael T. Goldfarb, MD; Marc D. Brown, MD; Charles N. Ellis, MD; John J. Voorhees, MD

Arch Intern Med. 1991;151(2):356-362.

Abstract
We compared the changes in renal function, blood pressure (BP), and concentrations of serum potassium, magnesium, and urate (uric acid) in two groups of patients not given transplants. Group 1, comprising 21 psoriatic patients, was treated with 14 mg/kg per day of oral cyclosporine for 4 weeks in a prospective, placebo-controlled study; group 2, comprising 28 patients with diverse cutaneous diseases, was given 6 mg/kg per day of oral cyclosporine for 1 to 3 months in a prospective, open-labeled study. Renal function (determined by serum urea nitrogen [SUN] and creatinine levels and urinalysis), BP, serum electrolyte levels (potassium and magnesium), and urate level were measured weekly for the first 4 weeks in both groups, and then, after 2 and 3 months of therapy, in group 2 only. During the first 4 weeks in group 1 patients, there were significant increases in values of SUN, creatinine, BP, potassium, and urate, and a significant decrease in the serum magnesium value. When data for the two groups were combined, the changes from pretherapy values in each of the above measures (except systolic BP) during the first 4 weeks correlated significantly with cyclosporine trough levels. In group 2, the changes that occurred in the first 4 weeks in the SUN value, SUN/creatinine ratio, and BP were magnified over the subsequent 8 weeks of treatment. In the combined group for the first 4 weeks of therapy, duration of therapy, independent of cyclosporine trough levels, correlated with changes in SUN, creatinine, and urate levels, but not with changes in the potassium or magnesium level or in BP. We conclude that the cyclosporine blood level was a better discriminant than cyclosporine dosage in the analysis of renal dysfunction and hypertension in these patients.

(Arch Intern Med. 1991;151:356-362)

Author Affiliations
From the Department of Dermatology (Drs Gupta, Goldfarb, Brown, Ellis, and Voorhees) and the Divisions of Nephrology (Dr Rocher) and Clinical Research (Dr Schmaltz), Department of Internal Medicine, University of Michigan, Ann Arbor. Dr Rocher is now with William Beaumont Hospital, Royal Oak, Mich.

Footnotes
Accepted for publication July 30, 1990.

Reprint requests to Renal Center, William Beaumont Hospital, 3601 W Thirteen Mile Rd, Royal Oak, MI 48072 (Dr Rocher).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pathogenesis of Gout
Choi et al.
ANN INTERN MED 2005;143:499-516.
FULL TEXT  

High Blood Pressure: A Side Effect of Drugs, Poisons, and Food
Grossman and Messerli
Arch Intern Med 1995;155:450-460.
ABSTRACT  

Treatment of Psoriasis
Greaves and Weinstein
NEJM 1995;332:581-589.
FULL TEXT